Objective To evaluate the application of donor lymphocyte infusion (DLI) after nonmyeloablative stem cell transplantation (NSCT) for hematologic malignancies.

• 目的探讨供者淋巴细胞输注(DLI)治疗非清髓性异基因造血干细胞移植后血液病复发的疗效。